KCS Wealth Advisory bought a new position in shares of Shire PLC (NASDAQ:SHPG) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,657 shares of the biopharmaceutical company’s stock, valued at approximately $722,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. acquired a new stake in shares of Shire during the second quarter worth $171,000. Neuberger Berman Group LLC grew its position in shares of Shire by 25.2% during the second quarter. Neuberger Berman Group LLC now owns 18,713 shares of the biopharmaceutical company’s stock worth $3,093,000 after acquiring an additional 3,769 shares during the last quarter. CIBC World Markets Inc. bought a new position in shares of Shire during the second quarter worth about $714,000. Stephens Inc. AR grew its position in shares of Shire by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 228 shares during the last quarter. Finally, Seven Eight Capital LP grew its position in shares of Shire by 18.5% during the second quarter. Seven Eight Capital LP now owns 4,494 shares of the biopharmaceutical company’s stock worth $743,000 after acquiring an additional 700 shares during the last quarter. 20.26% of the stock is currently owned by institutional investors and hedge funds.
Shire PLC (SHPG) opened at $139.19 on Friday. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $41,869.47, a P/E ratio of 9.57, a price-to-earnings-growth ratio of 0.75 and a beta of 1.41.
SHPG has been the subject of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Shire in a research report on Sunday, October 8th. ValuEngine upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. FBR & Co initiated coverage on shares of Shire in a research report on Thursday, October 19th. They set a “buy” rating and a $201.00 price objective for the company. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Finally, Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a research note on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. Shire has a consensus rating of “Hold” and an average target price of $212.18.
TRADEMARK VIOLATION WARNING: “KCS Wealth Advisory Takes $722,000 Position in Shire PLC (NASDAQ:SHPG)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/04/kcs-wealth-advisory-buys-shares-of-4657-shire-plc-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.